Structured Formula (Fluticasone Propionate 1)
Fluticasone Propionate
Product Images NDC 53217-164
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Fluticasone Propionate (NDC 53217-164). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Aidarex Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Table1 (Fluticasone Propionate 2)
This table presents drug-related adverse events associated with the application of Fluticasone in comparison to Vehicle, analyzed by frequency and severity. The study reported infection, eczema, viral warts, herpes simplex, erythema, burning, stinging, blisters, and dryness of the skin as the possible side effects.*
Table2 (Fluticasone Propionate 3)
Table 2 shows the adverse events reported in a pediatric open-label trial with 51 participants using Fluticasone twice daily. The adverse events included burning, dusky erythema, erythematous rash, facial telangiectasial, non-facial telangiectasia, and urticaria. The percentages of participants who experienced these events ranged from 2.0% to 4.9%. Additional details on the adverse events can be found in the accompanying text.*
Table3 (Fluticasone Propionate 4)
Table4 (Fluticasone Propionate 5)
The table displays the mean improvements over the baseline for clinical signs observed in four different studies comparing Fluticasone Propionate Cream with a vehicle. The clinical signs observed were erythema, thickening, and scaling. The results are shown in numerical values.*
Table5 (Fluticasone Propionate 6)
This is a table displaying the physician's assessment of clinical response for Fluticasone Propionate Cream used once or twice daily in two different studies. The table shows the percentage of patients who were cleared, showed excellent, good, fair, poor or worse clinical response in each study.*
Table6 (Fluticasone Propionate 7)
This is a table presenting clinical signs and symptoms in two studies with the use of Fluticasone Propionate cream. The table shows mean improvements over baseline for skin conditions such as erythema, pruritus, thickening, lichenification, vesiculation, and crusting. The improvements are compared between Fluticasone Propionate cream used once daily and twice daily in Study 1 and Study 2.*
Image Description (Fluticasone Propionate 8)
The text is not readable and appears to contain errors. It is not possible to generate a useful description.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
